The pharmacodynamics of intravenous bolus injections of 0.05, 0.10, 0.15, and 0.20 mg/kg of F(ab')2 fragments of the murine monoclonal antibody 7E3, 7E3-F(ab')2, directed against the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor of human platelets, were studied in groups of four patients with unstable angina pectoris. With 0.20 mg/kg, the template bleeding time prolonged from 6.3 +/-1.9 (mean +/-SD) to greater than 30 min; it subsequently decreased to 13 +/-7.8 min after 12 h and to 8.3 +/-1.5 min after 24 h. The number of unblocked GPIIb/IIIa receptors (preinfusion value, 32,000 +/-3,000 per platelet) decreased to 13 +/-7% of the preinfusion value 1 h after infusion, and then increased to 33 +/-10% at 12 h, 44 +/-8% at 24 h and 67 +/-7% at 72 h. The logarithm of the bleeding time was inversely proportional with the residual GPIIb/IIIa receptors (r = 0.73, P less than 0.0001). ADPinduced platelet aggregation (measured by changes in light transmittance in percent) decreased from 60 +/-5% before infusion to 1.5 +/-3% 1 h after infusion; it then increased to 29 +/-3% after 24 h and 39 +/-6% after 72 h. Platelet counts decreased by 16% at 1 h and returned to control values within 24 h. Proportionally smaller effects were seen at lower […] Research Article
frequently used antiplatelet agent, has shown some efficacy in treating and preventing these disorders (2) , raising the possibility that more potent inhibitors of platelet function may be more beneficial. Recent advances in the understanding of platelet physiology have identified a unique role for the platelet glycoprotein Ilb/Illa (GPIIb/IIIa)' receptor in mediating platelet aggregation (3, 4) , which most likely contributes to vaso-occlusive and thromboembolic phenomena. Therefore, we and others have been studying the potential of monoclonal antibodies to this receptor as therapeutic agents.
The F(ab')2 fragment of the murine monoclonal antibody 7E3, 7E3-F(ab')2, is more potent than aspirin in inhibiting platelet aggregation ex vivo and platelet thrombus formation in vivo in experimental models designed to simulate unstable angina and transient ischemic attacks (5) (6) (7) . It can also reduce both the time to reperfusion and the dose of recombinant tissue-type plasminogen activator needed to achieve reperfusion in dog models of acute myocardial infarction (8, 9) , and protect against acute reocclusion (8) (9) (10) . Other preliminary evidence indicates that the antibody can also prevent both experimental coronary artery thrombosis (11) and acute reocclusion after experimental coronary artery angioplasty-induced injury (12) . These data, together with toxicological studies in primates that did not identify serious acute toxicity (13-15), encouraged us to embark on a more extensive Phase I study in patients with unstable angina. We now report on the pharmacodynamics of increasing doses of 7E3-F(ab')2 in this patient population.
Methods
Patients. 16 patients aged 38-73 yr with unstable angina were studied. Diagnostic criteria were angina at rest for < 30 min in duration during the last 6 d before entry into the study and confirmation that the pain was of cardiac origin with electrocardiographic changes (ST segment elevations or depression, or T wave pseudonormalization or inversion) and angiographic evidence of at least 50% diameter stenosis in the ischemia-related artery. Patients with angiographically demonstrable intraluminal filling defects were considered candidates for rt-PA therapy (16) and so were not included in this study. Patients were excluded from participation if they had (a) high-grade stenosis supplying two myocardial zones that were inaccessible to angioplasty, (b) left main coronary disease with > 50% diameter stenosis, (c) a history of a hemorrhagic diathesis, (d) systolic blood pressure > 160 mm Hg or diastolic pressure > 90 mm Hg, (e) surgery within 8 wk of enrollment, (f) a recent arterial puncture in a noncompressible site, (g) diabetes mellitus for more than 5 yr, (h) prior exposure to a murine monoclonal antibody, or (i) abnormal baseline blood counts, blood chemistry measurements, or coagulation assays. The patients were given standard antianginal therapy including fl-adrenergic receptor blocking agents, intravenous nitroglycerin, and calcium antagonists, but were not treated with antiplatelet agents or heparin. A sample was considered to be reactive in the assay if it yielded an absorbance reading > 0.30 optical density (OD) units. The 0.30 OD cutoff was determined from a statistical analysis of the distribution of normal human sera (n = 181) under these specific assay conditions. All reactive samples were tested for reproducibility and to ensure a lack of reactivity on non-7E3-coated, BSA-blocked, microtiter plates. Confirmation as a positive response was established by inhibition experiments in which the HAMA-positive samples were preincubated (1 h, 45°C) with fluid-phase 7E3 F(ab')2 (0.1 mg/kg). Neutralization of sample reactivity in the presence of fluid-phase 7E3 is a requirement for consideration as a positive HAMA response. Inhibition experiments were also conducted with 0.1 mg/ml normal, intact mouse IgG (Jackson ImmunoResearch Laboratories) to further assess the specificity of the immune reaction.
Samples determined to be positive for HAMA were serially diluted to establish the maximum serum dilution (titer) which yielded an optical density value > 0.30. A sample was considered negative (titer < 1:20) if it yielded an OD < 0.30 at the 1:20 dilution.
Fibrinogen was assayed by a chronometric thrombin clotting assay (18) Platelet aggregation. In general, there was a dose-dependent increase in inhibition of platelet aggregation induced by both ADP and collagen, with much less, or no inhibition of ristocetin-induced aggregation (Table IV and Fig. 2 ). All five patients whose bleeding times rose to > 30 min at the 1-h time point had marked or total inhibition of platelet aggregation in response to both ADP and collagen, but only minor changes in ristocetin-induced aggregation, indicating that despite highgrade GPIIb/IIIa receptor blockade, the GPIb receptor remained available for binding of von Willebrand factor. The inhibition ofADP-and collagen-induced aggregation returned toward normal over 48-72 h, but some remaining inhibition was apparent, even at these time points (Fig. 2) .
There Fig. 3 . In addition, a more complex relationship was observed between percent residual GPIIb/IIIa, and platelet function parameters and bleeding time: log (% GPIIb/IIIa) = 1.1 -1.6 (dose) -0.005 (slope) -0.22 log (BT) + 0.11 log (AT) + 0.68 log (slope) with r = 0.95.
Prolongation of the bleeding time to > 15 min required reduction of the unblocked GPIIb/IIIa receptors to < 10,000 per platelet (7/8 values), whereas substantial inhibition of platelet aggregation occurred when the number of free GPIIb/ IlIa receptors was < 20,000 per platelet (Tables I-IV) .
Effect of 7E3-F(ab)2 on angina pectoris. 10 of the 16 patients were free of pain for the 24-h period before the antibody infusion and for at least 72 h thereafter. Three patients (nos. 11-2, 11-4, and IV-2) had chest pain during the 24 h before the infusion. All three were free of pain during the 12 h period immediately after infusion. Pain returned in patient IV-2 after 23 h. phase 7E3-F(ab)2 but not when the assay was performed in the presence of normal, intact mouse IgG. There were no obvious differences in this patient's response to the 7E3-F(ab32 infusion with regard to changes in platelet count (28% decrease at 1 shown). The hemoglobin and hematocrit values did not significance of this finding is unclear. Two other patients dechange significantly after injection of the antibody (Table V) .
veloped positive assays for IgG to 7E3-F(ab)2 several weeks after the infusion, indicating that the material is potentially Discussion immunogenic. This Phase I study demonstrates that infusion of 7E3-F(ab')2 at A significant correlation was observed between the log doses of 0.20 mg/kg to patients with unstable angina can probleeding time and the residual GPIIb/IIIa receptor density (r duce high-grade blockade of GPIIb/IIIa receptors (to 13±7% of = 0.73, P = 0.0001) indicating that the receptor density is an baseline) and marked inhibition of platelet aggregation inimportant determinant of the bleeding time.
duced by ADP and collagen. A marked prolongation of the The return of free GPIIb/IIIa receptors with time after inbleeding time (to > 30 min) with normalization within 24 h fusion of 0.20 mg/kg 7E3-F(ab')2 was relatively rapid, increaswas observed but this was not associated with spontaneous ing from 13±7% of the baseline value 1 h after injection of the hemorrhage or hemodynamic compromise. Platelet count reantibody, to 33±10% at 12 h, 44±8% at 24 h, and 67±7% at 72 ductions were mild and transient except in one patient who h. It is possible that clearance of antibody-coated platelets is sustained a more significant decrease to a nadir of 0.9 X 10g more rapid than normal, and provided platelet production ml, with a return toward normal over the next 2 d; there was matches the increased clearance, a more rapid return of free no obvious explanation for this patient's response, including a receptors would be expected. Direct platelet survival measurenegative evaluation for preexisting IgG antibodies to ments will be required to address this issue. Similarly, if the 7E3-F(ab)2. cohort of platelets in the spleen does not become coated with One patient had low levels of preexisting IgG anti-7E3-7E3-F(ab')2 to the same extent as peripheral blood platelets A. and recent preliminary evidence indicates that GPIIb/IIIa receptors may cycle between the pools (19). Strategies to prolong the receptor blockade may be aided by additional information on the mechanism(s) of the rapid return of free receptors. In group IV given 0.20 mg/kg of 7E3-F(ab')2, all patients had extensive GPIIb/IIIa receptor blockade and prolongation of the bleeding time to > 30 min at 1 h. Anginal pain did not occur within the first hours after injection of antibody in these patients, but was documented at 11 h in patient IV-3 and at 23 h in patient IV-2. The onset ofpain in patient IV-3 occurred at a time when the bleeding time was 10 min and the GPIIb/IIIa receptor density 37%; in patient IV-2 pain occurred at a time when the bleeding time was 7.0 min and the GPIIb/IIIa receptor density 49%. These observations suggest either that the mechanism of ischemic pain in these patients was not platelet mediated, or that very high grade blockade of GPIIb/IIIa receptors is required to prevent platelet thrombus formation and precipitation of ischemic pain. In view of the known pathophysiological relationship between atherosclerotic plaque rupture, platelet-rich localized thrombus formation contiguous to the site of rupture (20, 21), and ischemic coronary pain (22), we favor the latter hypothesis. This would entail that thrombogenicity of the vessel wall is either recurrent or persistent beyond the time zone of sufficient platelet inhibition with a single bolus injection of 7E3-F(ab')2. Further studies will indicate whether higher doses of the antibody fragment or repetitive injections of the antibody over a 24-48-h period might protect patients with unstable angina from recurrent ischemia until passivation of the thrombogenicity of the vessel wall has occurred.
Analysis of the present study, our previous study in a human (15) , and data obtained by us (6, 8, 10, 13, 23) and others (24, 25) even though they have -40% fewer GPIIb/IIIa receptors than normal individuals (26) . Reduction of the number of GPIIb/ Ila receptors to between 10,000 and 20,000 has a more profound effect on ADP-induced platelet aggregation, with nearly total abolition at -10,000 residual receptors (23) . The effect on the bleeding time, however, is only modest, unless the number of GPIIb/IIIa receptors is reduced to < 10,000. Interestingly, in the model developed by Folts to assess platelet thrombus formation in moderately stenosed (-70%) and damaged arteries, we found that platelet thrombus formation could be abolished in many animals by decreasing the number ofresidual GPIIb/IIIa receptors to between 10,000 and 20,000, a dose that did not completely inhibit platelet aggregation and rarely increased the bleeding time to > 10 min (23) . In contrast, in our previously described model designed to study thrombolysis of an acute coronary artery thrombus in severely stenosed (> 90%) blood vessels, in general, doses that would be expected to decrease the number of GPIIb/IIIa receptors to < 10,000 were required to obtain favorable results in speeding reperfusion, permitting recombinant tissue-type plasminogen activator dose reductions, and preventing reocclusion. In view ofthe greater stenosis in this model compared to the Folts model, the presence ofan initial thrombus, and the likelihood of residual thrombogenic material remaining after thrombolysis in this model, it is perhaps not surprising that higher-grade GPIIb/IIIa receptor blockade is required to have a favorable effect. In a preliminary report (27) , Takami et al. found that 1-1.5 mg/kg of a murine monoclonal antibody to pig platelet GPIIb/IIIa produced only modest increases in bleeding time but complete inhibition of ADP-induced platelet aggregation. They indicated that the plasma level ofthe Fab' reached a near saturating level (> 95%) after the infusion, but they did not measure the number ofblocked receptors directly. Since it is possible that equilibrium had not been established by 5 min, it may be that the extent of blockade was in fact < 95%. In addition, our data indicate that even when platelet aggregation has been abolished, additional 7E3-F(ab')2 can increase the bleeding time (23) . Moreover Hanson et al. (24) in baboons using the murine monoclonal antibody AP-2 are also consistent with our data since they found that at 0.4 mg/kg, a dose that only increased the bleeding from -5 min to < 10 min, there was a 77-82% decrease in ADP-induced platelet aggregation and 100% inhibition of collagen-induced aggregation. At a higher dose of AP-2 (1.0 mg/kg) the bleeding time rose to nearly 20 min. Moreover, a very high dose (10 mg/kg) of another monoclonal antibody (LJ-CP8) prolonged the bleeding time > 30 min while essentially eliminating platelet aggregation to ADP and collagen. All doses of AP-2 down to 0.2 mg/kg, which did not increase the bleeding time at all, significantly reduced platelet deposition on Dacron vascular grafts (0.2 mg/kg = 41%, 0.4 mg/kg = 51%, 1.0 mg/kg = 73%), demonstrating an antithrombotic effect at antibody concentrations that only had a modest effect on the bleeding time. Platelet GPIIb/IIIa receptors were not measured directly in this study. In another study (25) using LJ-CP8, 10 In summary, this study demonstrates that infusion of 7E3-F(ab')2 at 0.20 mg/kg transiently produces profound inhibition of platelet function without causing spontaneous hemorrhage. Additional studies will be required to assess whether this approach may be efficacious in the treatment of ischemic coronary syndromes.
